Biotech is benign
Biotech is benign
Europe’s continued blocking of GM imports is illegal, unjustified and founded on ignorance.
Science and Law: Swapping the lab for the law
Science and Law: Swapping the lab for the law
For scientists who want a career in law, the options are greater than ever – and some don’t even involve going back to school
Biotech sector keeps surging / Cancer drug news and FDA approvals create optimism
Biotech sector keeps surging / Cancer drug news and FDA approvals create optimism
Industry observers say the sector’s sea change from pessimism to optimism comes from two sources: Good news about experimental cancer drugs from a major scientific meeting this month; and a set of recent approvals by the Food and Drug Administration, whose new leadership is seen as more company-friendly.
Early stage biotechnology collaborations
Early stage biotechnology collaborations
The range of deals an early stage biotechnology company may enter into is wide (see box ‘What is an early stage biotechnology collaboration?’). This chapter examines, by reference to a few of the types of agreements that an early stage company may enter into, some of the key intellectual property (IP) and other legal issues that arise when undertaking such deals
FDA chief looks to speed diabetes, obesity drugs
FDA chief looks to speed diabetes, obesity drugs
Mark McClellan, commissioner of the Food and Drug Administration, said he wants to apply a fast-track review process normally reserved for drugs for terminal cancer and AIDS patients to drugs for diabetes and obesity.
Get updates by email
Editor
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
and Share
Reading
Translator
© Copyright - BiotechBlog — A thinkBiotech product
Recent Comments